Latest Patents

Patents imply intellectual property and it has a $ value that can be associated depending on the field and type of patent that is allocated. Patents also increase the enterprise value of the company and help prevent copy-cats from copying the idea without having royalt payments or licencing deals. We like it when companies get patents awarded!. To protect IP companies aggressively file provisional patents even before they have a working product. The below table provides a way to look at what has been done by companies and use this as a factor to make investment decisions.

     
Title Filing Date Publication Date Grant Date
Quinazoline pan-kras inhibitors 2023-2-03 2023-8-10
Sos1 inhibitors 2022-11-29 2023-5-04
2-amino imidazole derivatives 2022-11-04 2023-5-11
Methods for separation of enantiomers 2022-10-06 2023-4-13
Combination therapies using prmt5 inhibitors for the treatment of cancer 2022-10-06 2023-4-13
Combination therapies of kras g12d inhibitors with sos1 inhibitors 2022-10-04 2023-4-13
Combinations of kras g12d inhibitors with irinotecan and related methods of … 2022-10-04 2023-4-13
Combination therapies of kras g12d inhibitors with shp-2 inhibitors 2022-10-04 2023-4-13
Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods … 2022-10-04 2023-4-13
COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS 2022-10-04 2023-4-13
MTA-Cooperative PRMT5 Inhibitors 2022-9-12 2023-2-23
Processes and intermediates for synthesis of adagrasib 2022-9-08 2023-3-16
SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS 2022-8-26 2023-5-04
Kras g12d inhibitors 2022-7-20 2023-3-09
Aminopyridine-based mta-cooperative prmt5 inhibitors 2022-6-29 2023-1-05
Sos1 inhibitors 2022-6-21 2022-12-29
Combination therapies 2022-5-27 2023-4-01
Kras g12c inhibitors 2022-4-14 2022-10-20
Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer 2022-4-05 2022-10-20
Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer 2022-4-05 2022-10-20
Combination therapies 2022-3-23 2022-5-01
Mta-cooperative prmt5 inhibitors 2022-3-11 2022-9-15
Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, … 2022-3-10 2022-9-15
Combination therapies 2022-1-28 2022-8-04
Tetrahydropyridopyrimidine pan-kras inhibitors 2021-12-16 2022-6-23
Azaquinazoline pan-KRas inhibitors 2021-12-15 2023-3-09
Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer 2021-11-29 2022-1-01
Kras g12d inhibitors 2021-11-02 2022-5-12
Methods for treatment of lung cancers 2021-10-21 2023-8-30
Kras g12d inhibitors 2021-9-21 2023-8-02
Combination therapies 2021-9-15 2022-3-24
Crystalline forms of a kras g12c inhibitor 2021-9-10 2023-5-01
Crystalline forms of a KRAS G12C inhibitor 2021-9-10 2023-8-15
Kras g12d inhibitors 2021-8-03 2023-6-14
Sos1 inhibitors 2021-7-27 2022-2-03
Combination therapies 2021-3-25 2023-5-31
Combination therapies 2021-3-25 2022-6-29
Kras g12d inhibitors 2021-2-25 2023-9-07
Kras g12d inhibitors 2021-2-25 2022-1-20
Sos1 inhibitors 2021-2-23 2023-3-30
SOS1 INHIBITORS 2020-12-21 2022-3-23
COMPOUNDS INHIBITORS OF PRMT5 MTA-COOPERATIVES 2020-9-11 2022-1-26
Crystal form of polytyrosine kinase inhibitor, preparation method and … 2020-9-09 2022-4-26
KRAS G12D INHIBITORS 2020-8-27 2022-1-12
Kras g12c inhibitors 2020-6-30 2022-11-16
Kras g12c inhibitors 2020-6-12 2020-10-30
Kras g12c inhibitors 2020-5-07 2020-10-01
Naphthyridine derivatives as prc2 inhibitors 2020-4-21 2020-10-29
Mat2a inhibitors 2020-2-12 2020-8-20
Combination therapies 2019-9-10 2022-2-24
Combination therapies 2019-9-10 2022-2-10
Combination therapies 2019-9-09 2020-3-19
Combination therapies 2019-9-09 2022-2-10
Kras g12c inhibitors 2019-8-29 2021-7-29
Kras g12c inhibitors 2019-5-06 2019-11-14
Hinged connector 2019-1-25 2020-8-13
Kras g12c inhibitors 2018-11-07 2019-3-31
Lsd1 inhibitors 2018-6-22 2020-9-30
EZH2 inhibitors 2018-3-14 2019-4-23 2019-4-23
Lsd1 inhibitors 2016-11-03 2017-5-11
Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors 2013-7-19 2013-11-21
Inhibitors of protein tyrosine kinase activity 2013-2-14 2013-6-27
Inhibitors of VEGF receptor and HGF receptor signaling 2011-12-08 2012-12-11 2012-12-11